News and updates
Publication of EHA Annual General Meeting 2024 minutes
The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024.
What to expect from European Affairs at EHA2024
European Affairs gives a voice to hematology professionals in Europe.
Streamlining SoHO Management in EU Hospitals
The European Commission's Directorate-General for Health and Food Safety (DG SANTE) is committed to improving the management of Substances of Human Origin (SoHO) in EU hospitals.
The European Parliament adopts the Regulation on Substances of Human Origins (So…
On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).
Parliament puts final stamp on the European Health data Space
On April 24, the European Parliament gave its final endorsement to the regulation on the European Health Data Space (EHDS).
EHA attends the EuNet-INNOCHRON Final Conference
The EuNet-INNOCHRON Final Conference, a significant event in the field of hematology, took place in Chania, Crete, Greece from April 4-6, 2024.
EU Parliament agrees on pharmaceutical legislation stance
On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.
EHA ‘Excellence in Hematology’ Survey now online
Excellence in Hematology is created together. Would you help us out? This week, we’re starting an important research endeavor – our ‘Excellence in hematology’ survey.
EHA mapping of adolescent and young adult (AYA) hematology patient care
EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.
Cancer Medicines Forum workshop April 5: a way forward for treatment optimizatio…
The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).
The ‘i4MDS’ consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
EHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Urgent action needed to avoid widespread shortage of in-vitro diagnostic tests
In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.
Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU adv…
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) …
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy…